World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
33510
World Ranking
11681
National Ranking
164

Susana Puig publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Susana Puig sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 651 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Susana Puig D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Susana Puig sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Susana Puig is affiliated with the University of Barcelona in Spain. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Oncology, Dermatology, Epidemiology, Molecular Biology, and Immunology.

The scientist's work centers on topics such as Cutaneous Melanoma Detection and Management, Nonmelanoma Skin Cancer Studies, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Skin Protection and Aging, Cutaneous lymphoproliferative disorders research, and CAR-T cell therapy research.

Susana Puig has published extensively in academic venues, frequently contributing to:

  • Journal of the European Academy of Dermatology and Venereology
  • EJC Skin Cancer
  • Actas Dermo-Sifiliográficas
  • Journal of the American Academy of Dermatology
  • British Journal of Dermatology

Their recent papers include:

  • "Human-computer collaboration for skin cancer recognition," 2020, Nature Medicine
  • "Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo," 2020, JAMA Oncology
  • "Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma," 2022, Nature Medicine
  • "Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial," 2021, The Lancet Oncology
  • "Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial," 2020, Journal of Clinical Oncology

Their frequent co-authors include:

  • Josep Malvehy
  • Cristina Carrera
  • Sebastián Podlipnik
  • Javiera Pérez-Ánker
  • Élisa Cinotti

Best Publications

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet

    Giuseppe Argenziano;H.Peter Soyer;Sergio Chimenti;Renato Talamini

  • A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

    Corine Bertolotto;Fabienne Lesueur;Sandy Giuliano;Thomas Strub

  • Human–computer collaboration for skin cancer recognition

    Philipp Tschandl;Christoph Rinner;Zoe Apalla;Giuseppe Argenziano

  • Genome-wide association study identifies three loci associated with melanoma risk.

    D Timothy Bishop;Florence Demenais;Mark M Iles;Mark Harland

  • Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma‐prone families from three continents

    Alisa M Goldstein;May Chan;Mark Harland;Nicholas K Hayward

  • High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL

    Alisa M. Goldstein;May Chan;Mark Harland;Elizabeth M. Gillanders

  • A DNA methylation fingerprint of 1628 human samples

    Augustin F. Fernandez;Yassen Assenov;Jose Ignacio Martin-Subero;Balazs Balint

  • Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification: an open, web-based, international, diagnostic study.

    Philipp Tschandl;Noel Codella;Bengü Nisa Akay;Giuseppe Argenziano

  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

    Alexander M.M. Eggermont;Michal Kicinski;Christian U. Blank;Mario Mandala

  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Alexander M M Eggermont;Christian U Blank;Mario Mandalà;Georgina V Long

  • Dermoscopy Improves Accuracy of Primary Care Physicians to Triage Lesions Suggestive of Skin Cancer

    Giuseppe Argenziano;Susana Puig;Iris Zalaudek;Francesco Sera

  • Dermoscopic evaluation of amelanotic and hypomelanotic melanoma

    Menzies Sw;Kreusch J;Byth K;Pizzichetta Ma

  • Prevalence of psoriasis in Spain (Epiderma Project: phase I)

    C Ferrándiz;Bordas X;García-Patos;S Puig

  • Genome-wide association study identifies three new melanoma susceptibility loci

    Jennifer H. Barrett;Mark M. Iles;Mark Harland;John C. Taylor

  • Entodermoscopy: a new tool for diagnosing skin infections and infestations.

    Iris Zalaudek;Jason Giacomel;Horacio Cabo;Alessandro Di Stefani

  • Dermoscopy of Bowen's disease.

    I. Zalaudek;G. Argenziano;B. Leinweber;L. Citarella

  • Standardization of terminology in dermoscopy/dermatoscopy: Results of the third consensus conference of the International Society of Dermoscopy.

    Harald Kittler;Ashfaq A. Marghoob;Giuseppe Argenziano;Cristina Carrera

  • Confirmation of a double-hit model for the NF1 gene in benign neurofibromas.

    Eduard Serra;Susana Puig;David Otero;Antonia Gaona

  • BCN20000: Dermoscopic Lesions in the Wild.

    Marc Combalia;Noel C. F. Codella;Veronica Rotemberg;Brian Helba

Frequent Co-Authors

Josep Malvehy
Josep Malvehy University of Barcelona
Giuseppe Argenziano
Giuseppe Argenziano University of Campania "Luigi Vanvitelli"
Iris Zalaudek
Iris Zalaudek University of Trieste
Ashfaq A. Marghoob
Ashfaq A. Marghoob Memorial Sloan Kettering Cancer Center
Giovanni Pellacani
Giovanni Pellacani Sapienza University of Rome
Nelleke A. Gruis
Nelleke A. Gruis Leiden University Medical Center
Nicholas K. Hayward
Nicholas K. Hayward QIMR Berghofer Medical Research Institute
Alisa M. Goldstein
Alisa M. Goldstein National Institutes of Health
Johan Hansson
Johan Hansson Karolinska Institute
Graham J. Mann
Graham J. Mann Australian National University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine in the USA offers many online degree options for students seeking flexible routes to a healthcare career. Aspiring nurses, nurse practitioners, and healthcare professionals can benefit from a variety of accelerated and fast-track online programs.

For registered nurses aiming for leadership or advanced clinical roles, accelerated dnp programs online provide the opportunity to earn a Doctor of Nursing Practice degree more quickly. Those looking for easier study paths can explore easiest dnp programs that offer flexible schedules and less intensive coursework.

Students interested in starting their careers quickly can consider fast track medical training programs, including Licensed Practical Nurse (LPN) courses that can be completed in shorter timeframes. Additionally, for those holding a master’s degree, shortest post master's pmhnp online programs allow for specialization as a Psychiatric Mental Health Nurse Practitioner in an accelerated format.

Exploring these online options can open new career pathways in medicine, providing greater flexibility and faster entry into the healthcare workforce.

Best Scientists Citing Susana Puig

Trending Scientists

Recently Published Articles